ABSCIENCES (EPA:AB) AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
Transparency directive : regulatory news
09/05/2023 18:06